Veraxa Biotech AG - Post de-SPAC

Overview

Compare with another stock.

• TickerVRXA on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersV8¹
• Incorporated inSwitzerland²
• Business addressTalacker 35, Zurich, 8001²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

PubCo, the legal entity named Veraxa Biotech Holding AG, was incorporated under the laws of Switzerland on June 25, 2025 as a stock corporation ( Aktiengesellschaft ) solely for the purpose of effectuating the Business Combination, which was consummated on June 10, 2026. See “ Explanatory Note ” for further details about the Business Combination. See also a description of the material terms of the Business Combination as described in the Prospectus in the section entitled, “ Proposal No. 1—The Business Combination Proposal—The Business Combination Agreement. ” Prior to the Business Combination, PubCo owned no material assets other than its interest in Merger Sub, which was formed in connection with the Business Combination, and does not operate any business.³ From its latest annual report

Corporate structure

Veraxa Biotech AG - Post de-SPAC sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Veraxa Biotech AG - Post de-SPAC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerChristoph Rudiger Antz Jun 9, 2026 to now⁴
• Chief financial officerTorsten Georg Friedrich Buergermeister Jun 9, 2026 to Aug 20, 2026⁵
• Chief financial officerHalem Carl Von Aug 20, 2026 to Sep 14, 2026⁶
• Chief financial officerRaju Sudir Willener Sep 14, 2026 to now⁷

Former names

• Veraxa Biotech Holding AGJul 31, 2025 to Aug 13, 2026²

Timeline

1. Jun 9, 2026New chief executive Christoph Rudiger Antz becomes CEO⁴

Filings

54 filings to the SEC since October 2021: 1 annual reports, 11 insider forms, 5 large holders, 37 other. The latest 20:

1. Oct 15, 20266-K EDGAR
2. Sep 14, 20263 EDGAR
3. Sep 4, 2026424B3 EDGAR
4. Sep 4, 2026424B3 EDGAR
5. Sep 4, 20266-K EDGAR
6. Aug 31, 20264 EDGAR
7. Aug 31, 20264 EDGAR
8. Aug 24, 20266-K EDGAR
9. Aug 20, 20263 EDGAR
10. Aug 13, 2026SCHEDULE 13G/A EDGAR
11. Aug 10, 2026424B5 EDGAR
12. Aug 10, 2026424B5 EDGAR
13. Aug 6, 2026EFFECT EDGAR
14. Aug 6, 2026EFFECT EDGAR
15. Aug 5, 2026F-1/A EDGAR
16. Aug 5, 2026F-1/A EDGAR
17. Jul 31, 2026F-1 EDGAR
18. Jul 31, 2026F-1 EDGAR
19. Jul 31, 20266-K EDGAR
20. Jul 27, 20266-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• AQR CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 1 filing Aug 13, 2026¹³
• David Lukas DeckSCHEDULE 13D, 1 filing Jun 16, 2026¹⁴
• Molecular Biology Laboratory EuropeanSCHEDULE 13D, 1 filing Jun 16, 2026¹⁵
• Gilbert Edgar SchoeniSCHEDULE 13D, 1 filing Jun 15, 2026¹⁶
• Xlife Sciences AGSCHEDULE 13D, 1 filing Jun 15, 2026¹⁷

SEC filer profile

How Veraxa Biotech AG - Post de-SPAC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARVeraxa Biotech AG - Post de-SPAC¹
• CIK0002079109
• Filer statusNon-accelerated filer an emerging growth company; a shell company³
• Incorporated inSwitzerland³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressTalacker 35, Zurich, 8001, Switzerland¹
• Phone41443858450¹
• Shares outstanding141,407,813 Ordinary Share shares; 22,706,305 Warrant To Purchase shares as of Jun 10, 2026³
• AuditorGRASSI & CO., CPAs, P.C, New York PCAOB ID 606; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceJul 31, 2025¹
• Filings54 in all: 3 (9), 6-K (8), F-4/A (5), CORRESP (4), SCHEDULE 13D (4), 424B3 (3), EFFECT (3), UPLOAD (3)¹
  All 19 form types

  4 (2), 424B5 (2), F-1 (2), F-1/A (2), 20-F (1), 425 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), F-4 (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (20-F) Jun 16, 2026

Securities registered for trading

From the cover page of the 20-F filed Jun 16, 2026 (Section 12(b) of the Exchange Act).³